From Old Competence Destruction to New Competence Access: Evidence from the Comparison of Two Discontinuities in Anticancer Drug Discovery

References

• Agarwal R., Helfat C. E. Strategic renewal of organizations. Organ. Sci. (2009) 20(2):281–293Link, Google Scholar
• Ahuja G., Katila R. Where do resources come from? The role of idiosyncratic situations. Strategic Management J. (2004) 25(8–9):887–907Crossref, Google Scholar
• American Cancer Society Cancer facts and figures 2000. (2000) . Retrieved March 10, 2008, http://ww2.cancer.org/downloads/STT/F&F00.pdfGoogle Scholar
• American Cancer Society Cancer facts and figures 2004. (2004) . Retrieved March 25, 2009, http://ww2.cancer.org/downloads/STT/CAFF_finalPWSecured.pdfGoogle Scholar
• Amit R., Schoemaker P. J. H. Strategic assets and organizational rent. Strategic Management J. (1993) 14(1):33–46Crossref, Google Scholar
• Barney J. B. Strategic factor markets—Expectations, luck, and business strategy. Management Sci. (1986) 32(10):1231–1241Link, Google Scholar
• Barney J. B. Firm resources and sustained competitive advantage. J. Management (1991) 17(1):99–120Crossref, Google Scholar
• Bazell R.Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer (1998) (Random House, New York) Google Scholar
• Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, Imanitib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discovery (2002) 1:493–502Crossref, Google Scholar
• Cattani G. Preadaptation, firm heterogeneity, and technological performance: A study on the evolution of fiber optics, 1970–1995. Organ. Sci. (2005) 16(6):563–580Link, Google Scholar
• Chabner B. A., Roberts T. G. Chemotherapy and the war on cancer. Nature Rev. Cancer (2005) 5:65–72Crossref, Google Scholar
• Chemical and Engineering News List of top pharmaceuticals. (2005) 83(25, Special issue). http://pubs.acs.org/cen/coverstory/83/8325/8325list.htmlGoogle Scholar
• Christensen C. M.The Innovator's Dilemma: The Revoluationary Book that Will Change the Way You Do Business (1997) (Harvard Business School Press, Boston) Google Scholar
• Colwell R. R. Fulfilling the promise of biotechnology. Biotechnology Adv. (2002) 20(3–4):215–228Crossref, Google Scholar
• Dierickx I., Cool K. Asset stock accumulation and sustainability of competition advantage. Management Sci. (1989) 35(12):1504–1511Link, Google Scholar
• Drews J. Into the 21st century: Biotechnology and the pharmaceutical industry in the next ten years. Biotechnology (1993) 11(3):S16–S20Crossref, Google Scholar
• Eggers J. P., Kaplan S. Cognition and renewal: Comparing CEO and organizational effects on incumbent adaptation to technical change. Organ. Sci. (2009) 20(2):461–477Link, Google Scholar
• Ethiraj S. K., Kale P., Krishnan M. S., Singh J. V. Where do capabilities come from and how do they matter? A study in the software services industry. Strategic Management J. (2005) 26(1):25–45Crossref, Google Scholar
• Feldman M. The locational dynamics of the US biotech industry: Knowledge externalities and the anchor hypothesis. Indust. Innovation (2003) 10(3):311–329Crossref, Google Scholar
• Ferrera N., Hillan K. J., Gerber H.-P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discovery (2004) 3:391–400Crossref, Google Scholar
• Gatignon H., Tushman M. L., Smith W., Anderson P. A structural approach to assessing innovation: Construct development of innovation locus, type, and characteristics. Management Sci. (2002) 48(9):1103–1122Link, Google Scholar
• Gibbons A. Biotech pipeline: Bottleneck ahead. Science (1991) 254(5030):369–370Crossref, Google Scholar
• Groysberg B., Lee L.-E., Nanda A. Can they take it with them? The portability of star knowledge workers' performance. Management Sci. (2008) 54(7):1213–1230Link, Google Scholar
• Hammond E., Johnson M. Credit Suisse leads bank sector higher. Financial Times (2009) July 23). http://www.ft.com/cms/s/o/ab0757d0-7773-11de-8c68-00144feaGoogle Scholar
• Hannan M. T., Freeman J. Structural inertia and organizational change. Amer. Sociol. Rev. (1984) 49(2):149–164Crossref, Google Scholar
• Helfat C. E., Lieberman M. B. The birth of capabilities: Market entry and the importance of pre-history. Indust. Corporate Change (2002) 11(4):725–760Crossref, Google Scholar
• Kaplan S., Murray F., Phillips N., Sewell G., Griffiths D. Entrepreneurship and the construction of value in biotechnology. Technology and Organization: Essays in Honour of Joan Woodward. Research in the Sociology of Organizations (2008) 29(Emerald Publishing, Bingley, UK) 107–147Google Scholar
• Lacetera N., Cockburn I. M., Henderson R., Baum J. A. C., McGahan A. M. Do firms change capabilities by hiring new people? A study of the adoption of science-based drug discovery. Business Strategy over the Industry Life Cycle. Advances in Strategic Management (2004) 21(Emerald Publishing, Bingley, UK) 133–159Crossref, Google Scholar
• Leader B., Baca Q. J., Golan D. E. Protein therapeutics: A summary and pharmacological classification. Nature Rev. Drug Discovery (2008) 7:21–39Crossref, Google Scholar
• Lieberman M. B., Montgomery D. B. First-mover advantages. Strategic Management J. (1988) 9(S1):41–58Crossref, Google Scholar
• Lu Z. J., Comanor W. S. Strategic pricing of new pharmaceuticals. Rev. Econom. Statistics (1998) 80(1):108–118Crossref, Google Scholar
• Marx M. T. Essays on employee noncompete agreements. (2009) . Unpublished doctoral dissertation, Harvard Business School, BostonGoogle Scholar
• Mitchell W. Dual clocks: Entry order influences on incumbent and newcomer market share and survival when specialized assets retain their value. Strategic Management J. (1991) 12(2):85–100Crossref, Google Scholar
• Montgomery C. A., Wernerfelt B. Diversification, Ricardian rents, and Tobin's Q. RAND J. Econom. (1988) 19(4):623–632Crossref, Google Scholar
• Morton L. T., Moore R. J.A Chronology of Medicine and Related Sciences (1997) (Scolar Press, Hants, UK) Google Scholar
• Mowery D. C., Rosenberg N.Paths of Innovation: Technological Change in 20th-Century America (1998) (Cambridge University Press, Cambridge, UK) Crossref, Google Scholar
• Nature Nature milestones: Cancer. (2006) . Retrieved April 24, 2009, http://www.nature.com/milestones/milecancer/timeline.htmlGoogle Scholar
• Nature Nature milestones: DNA technologies. (2007) . Retrieved April 24, 2009, http://www.nature.com/milestones/miledna/timeline.htmlGoogle Scholar
• Pearson A. E., Hurstak J. M. Johnson & Johnson in the 1990s. (1992) . HBS Case 9-393-001, Harvard Business School, BostonGoogle Scholar
• Penrose E.The Theory of the Growth of the Firm (1959) (Oxford University Press, Oxford, UK) Google Scholar
• Puranam P., Singh H., Chaudhuri S. Integrating acquired capabilities: When structural integration is (un)necessary. Organ. Sci. (2009) 20(2):313–328Link, Google Scholar
• Rang H. P., Rang H. P. The drug discovery process: general principles and some case histories. Drug Discovery and Development: Technology in Transition (2006) (Churchill Livingstone, Philadelphia) 43–56Google Scholar
• Rothaermel F. T. Incumbent's advantage through exploiting complementary assets via interfirm cooperation. Strategic Management J. (2001) 22(6–7):687–699Crossref, Google Scholar
• Rumelt R. P., Teece D. J. Theory, strategy, and entrepreneurship. The Competitive Challenge: Strategies for Industrial Innovation and Renewal (1987) (Ballinger, Cambridge, MA) 137–158Google Scholar
• Simonian H., Jack A. Novartis wins Chiron after sweetening its offer. Financial Times (2005) October 31). http://www.ft.com/cms/s/0/b9c4db34-49fb-11da-b8b1-0000779e2340.html#axzz1C5uVW1dyGoogle Scholar
• Simonian H., Jack A. Roche completes Genentech deal. Financial Times (2009) March 27). http://www.ft.com/cms/s/0/323d1670-1a6f-11de-9f91-0000779fd2ac.htmlGoogle Scholar
• Sørensen J. B., Stuart T. E. Aging, obsolescence and innovation. Admin. Sci. Quart. (2000) 45(1):81–112Crossref, Google Scholar
• Sosa M. L. Application-specific R&D capabilities and the advantage of incumbents: Evidence from the anticancer drug market. Management Sci. (2009a) 55(8):1409–1422Link, Google Scholar
• Sosa M. L. High-risk radical innovation and the role of de novo firms in the dynamics of creative destruction: Evidence from gene therapy research. (2009b) Presentation, EGOS Conference 2009July 2(European Group for Organizational Studies, Barcelona) Google Scholar
• Sutton J.Technology and Market Structure: Theory and Structure (1998) (MIT Press, Cambridge, MA) Google Scholar
• Teece D. J. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy. Res. Policy (1986) 15(6):285–305Crossref, Google Scholar
• Tilton J. E.International Diffusion of Technology: The Case of Semiconductors (1971) (Brookings Institution, Washington, DC) Google Scholar
• Tripsas M. Unraveling the process of creative destruction: Complementary assets and incumbent survival in the typesetter industry. Strategic Management J. (1997) 18(S1):119–142Crossref, Google Scholar
• Tushman M., Anderson P. Technological discontinuities and organizational environments. Admin. Sci. Quart. (1986) 31(3):439–465Crossref, Google Scholar
• Tyle P., Ram B. P., Tyle P., Ram B. P. Monoclonal antibodies, immunoconjugates and liposomes as targeted therapeutic systems. Targeted Therapeutic Systems (1990) (Marcel Dekker, New York) 3–23Google Scholar
• Vasella D., Slater R.Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History (2003) (HarperCollins, New York) Google Scholar
• Walsh G.Biopharmaceuticals: Biochemistry and Biotechnology (2003) 2nd ed.(John Wiley & Sons, Chichester, UK) Google Scholar
• Weber J. A big company that works: J&J's Ralph Larsen gives his units a lot of latitude—And they produce. Bus. Week (1992) 3264(4):124–127Google Scholar
• Wernerfelt B. A resource-based view of the firm. Strategic Management J. (1984) 5(2):171–180Crossref, Google Scholar
• Williams C., Mitchell W. Focusing firm evolution: The impact of information infrastructure on market entry by U.S. telecommunications companies, 1984–1998. Management Sci. (2004) 50(11):1561–1575Link, Google Scholar